Table 1 Comparison of clinical characteristics of patients in D2 + PAND group and D2 group
Variables | Scope of lymph node dissection | χ2 | p-value | |
|---|---|---|---|---|
D2 + PAND (n = 40) | D2 (n = 46) | |||
Sex | 0.427 | 0.514 | ||
Male | 27 (67.5%) | 34 (73.9%) | ||
Female | 13 (32.5%) | 12 (26.1%) | ||
Age (year) | 0.054 | 0.817 | ||
< 60 | 21 (52.5%) | 23 (50%) | ||
≥ 60 | 19 (47.5%) | 23 (50%) | ||
16a2 area | 3.629 | 0.057 | ||
Negative | 17 (42.5%) | 29 (63.0%) | ||
Positive | 23 (57.5%) | 17 (37.0%) | ||
16b1 area | 2.120 | 0.145 | ||
Negative | 9 (22.5%) | 17 (37.0%) | ||
Positive | 31 (77.5%) | 29 (63.0%) | ||
Chemotherapy regimens | 0.367 | 0.545 | ||
Dual drug combination | 30 (75%) | 37 (80.4%) | ||
Triple drug combination | 10 (25%) | 9 (19.6%) | ||
Tumor location | 4.737 | 0.192 | ||
Proximal stomach | 3 (7.5%) | 10 (21.7%) | ||
Middle stomach | 14 (35%) | 12 (21.7%) | ||
Distal stomach | 20 (50%) | 23 (54.3%) | ||
Total stomach | 3 (7.5%) | 1 (2.2%) | ||
Borrmann type | 0.863 | 0.834 | ||
Borrmann I | 10 (11.6%) | 6 (13%) | ||
Borrmann II | 54 (62.8%) | 28 (28%) | ||
Borrmann III | 13 (15.1%) | 8 (17.4%) | ||
Borrmann IV | 9 (10.5%) | 4 (8.7%) | ||
Grade of differentiation | 0.156 | 0.693 | ||
Poor | 26 (65%) | 28 (60.9%) | ||
Moderate | 14 (35%) | 18 (39.1%) | ||
Nerve invasion | 0.140 | 0.709 | ||
Negative | 21 (52.5%) | 26 (56.5%) | ||
Positive | 19 (47.5%) | 20 (43.5%) | ||